Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92,291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators. d'Emden MC, et al. Among authors: li l. Diabetologia. 2015 Sep;58(9):2200. doi: 10.1007/s00125-015-3693-6. Diabetologia. 2015. PMID: 26186882 Free article. No abstract available.
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Burgess DC, et al. Among authors: li l. Eur Heart J. 2010 Jan;31(1):92-9. doi: 10.1093/eurheartj/ehp377. Epub 2009 Sep 29. Eur Heart J. 2010. PMID: 19797259 Clinical Trial.
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators. d'Emden MC, et al. Among authors: li l. Diabetologia. 2014 Nov;57(11):2296-303. doi: 10.1007/s00125-014-3344-3. Epub 2014 Aug 23. Diabetologia. 2014. PMID: 25149070 Clinical Trial.
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC; FIELD investigators. Waldman B, et al. Among authors: li l. Lancet Diabetes Endocrinol. 2018 Apr;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26. Lancet Diabetes Endocrinol. 2018. PMID: 29496472 Clinical Trial.
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.
Ong KL, Wu L, Januszewski AS, O'Connell R, Xu A, Scott RS, Sullivan DR, Rye KA, Li H, Ma RC, Li L, Gebski V, Jenkins AJ, Jia W, Keech AC. Ong KL, et al. Among authors: li h, li l. Diab Vasc Dis Res. 2021 Jul-Aug;18(4):14791641211032547. doi: 10.1177/14791641211032547. Diab Vasc Dis Res. 2021. PMID: 34275349 Free PMC article. Clinical Trial.
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
West M, Kirby A, Stewart RA, Blankenberg S, Sullivan D, White HD, Hunt D, Marschner I, Janus E, Kritharides L, Watts GF, Simes J, Tonkin AM; LIPID Study Group *. West M, et al. J Am Heart Assoc. 2022 Mar;11(5):e020745. doi: 10.1161/JAHA.121.020745. Epub 2022 Feb 18. J Am Heart Assoc. 2022. PMID: 35179040 Free PMC article.
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy.
Rao BN, Quinn N, Januszewski AS, Peto T, Brazionis L, Aryal N, O'Connell RL, Li L, Summanen P, Scott R, O'Day J, Keech AC, Jenkins AJ; FIELD Study Group. Rao BN, et al. Among authors: li l. Diabetes Res Clin Pract. 2022 Apr;186:109835. doi: 10.1016/j.diabres.2022.109835. Epub 2022 Mar 18. Diabetes Res Clin Pract. 2022. PMID: 35314259
Corrigendum to "Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy" [Diab. Res. Clin. Pract. 186 (2022) 109835].
Rao BN, Quinn N, Januszewski AS, Peto T, Brazionis L, Aryal N, O'Connell RL, Li L, Summanen P, Scott R, O'Day J, Keech AC, Jenkins AJ; FIELD Study Group. Rao BN, et al. Among authors: li l. Diabetes Res Clin Pract. 2023 Feb;196:110234. doi: 10.1016/j.diabres.2022.110234. Epub 2023 Jan 4. Diabetes Res Clin Pract. 2023. PMID: 36609014 No abstract available.
Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Sheu A, O'Connell RL, Jenkins AJ, Tran T, Drury PL, Sullivan DR, Li L, Colman P, O'Brien R, Kesäniemi YA, Center JR, White CP, Keech AC. Sheu A, et al. Among authors: li l. Diabetes Metab Res Rev. 2023 Jul;39(5):e3631. doi: 10.1002/dmrr.3631. Epub 2023 Mar 19. Diabetes Metab Res Rev. 2023. PMID: 36893361 Free PMC article. Clinical Trial.
92,291 results
You have reached the last available page of results. Please see the User Guide for more information.